BioSpace News Archive

Biogen Inc. (Nasdaq: BIIB) announced today that it will hold an Investor Day focused on its broad pipeline across neuroscience and related therapeutic adjacencies.

Rising prevalence of infectious diseases including SARS-CoV-2 infection and technological advancements in diseases diagnostics to spur market growth.

Increasing significance of contract research organizations in drug discovery initiatives is driving revenue growth of the market.

Today, Bristol Myers Squibb (NYSE: BMY) and GRYT Health unveiled the “Advocacy Exchange,” an evolution of the existing COVID Advocacy Exchange, an enduring community built to support patient advocacy organizations by providing access to educational resources, encouraging ongoing dialogue, and sharing best practices among participants.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that the company will participate in 1x1 meetings with investors and potential partners at BIO Digital 2021 being held June 10-11 and June 14-18, 2021.

Aethlon Medical, Inc. announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a registered direct offering of 1,380,555 shares of its common stock, at a purchase price per share of $9.00, priced at-the-market under Nasdaq rules.

Ossianix, an antibody engineering company, and the University of Graz announced the publication of a preclinical study that describes discovery of highly potent neutralizing single domain shark antibodies directed against the SARS-CoV-2 spike protein.

Matrix Clinical Solutions, a Matrix Medical Network® (Matrix) business, today announced the appointment of Dawn Carter as President of the Employee Health business unit

Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, announced it has initiated patient enrollment and screening in its Phase 1 imaging study evaluating VMT01 for the treatment of metastatic melanoma.

A corporate presentation by Maria L. Maccecchini, Ph.D., CEO of Annovis Bio, will be available to registered attendees beginning at 9:00 a.m. ET on June 10.